Emcure Pharmaceuticals Ltd (EMCURE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039308, "name": "Emcure Pharma", "stock_name": "Emcure Pharma", "full_name": "Emcure Pharmaceuticals Ltd", "name_url": "stocks-analysis/emcure-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,519.85", "chg": 105.05, "chgp": "7.43%", "dir": 1, "prev_price": "1,414.80", "mcapval": "26,751.00 Cr", "mcap": "Small Cap", "scripcode": 544210, "symbol": "EMCURE", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE168P01015", "curr_date": "Mar 09", "curr_time": "", "bse_nse_vol": "27.61 lacs", "exc_status": "Active", "traded_date": "Mar 09, 2026", "traded_date_str": "2026 03 09", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/emcure-pharma-10039308-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Emcure Pharmaceuticals Ltd Hits Intraday High with 7.79% Surge on 9 March 2026", "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-intraday-high-with-779-surge-on-9-march-2026-3880394", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EmcurePharmaceu_priceRelatedfactors_3880394.png", "date": "2026-03-09 14:04:54", "description": "Emcure Pharmaceuticals Ltd demonstrated a robust intraday performance on 9 Mar 2026, surging to an intraday high of Rs 1,537, marking an 8.64% increase from its previous close. The stock closed with a notable gain of 7.79%, significantly outperforming its sector and broader market indices amid a generally negative market environment." }, { "title": "Emcure Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-3864097", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/EmcurePharmaceu_mojoScore_3864097.png", "date": "2026-03-02 10:10:36", "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 02 March 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, returns, and overall outlook." }, { "title": "Emcure Pharmaceuticals Declines 3.37%: Mixed Technical Signals and Valuation Concerns Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-declines-337-mixed-technical-signals-and-valuation-concerns-shape-the-week-3849082", "imagepath": "", "date": "2026-02-21 09:01:16", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Feb:</strong> Emcure upgraded to Buy on strong financials and bullish technicals</p>\n <p><strong>17 Feb:</strong> Technical momentum shifts amid mixed market signals</p>\n <p><strong>18 Feb:</strong> Downgrade to Hold reflecting mixed technical and valuation signals</p>\n <p><strong>20 Feb:</strong> Week closes at ₹1,438.55 (-3.37%) versus Sensex +0.39%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹1,488.65</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</..." }, { "title": "Emcure Pharmaceuticals Downgraded to Hold Amid Mixed Technical and Valuation Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-3846463", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EmcurePharmaceu_mojoScore_3846463.png", "date": "2026-02-19 08:24:02", "description": "Emcure Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold as of 18 Feb 2026, reflecting a nuanced reassessment across quality, valuation, financial trends, and technical indicators. Despite strong financial performance and market-beating returns over the past year, evolving technical signals and valuation concerns have tempered the outlook, prompting a more cautious stance from analysts." }, { "title": "Emcure Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-3843675", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EmcurePharmaceu_technicaldot_3843675.png", "date": "2026-02-17 08:07:32", "description": "Emcure Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of mid-February 2026. Despite a recent dip in price, key indicators such as the MACD and moving averages continue to suggest underlying strength, while other metrics like RSI and Dow Theory remain inconclusive. This article analyses the latest technical signals and market context to provide a comprehensive view of Emcure’s current positioning within the Pharmaceuticals & Biotechnology sector." }, { "title": "Emcure Pharmaceuticals Upgraded to Buy on Strong Financials and Bullish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-upgraded-to-buy-on-strong-financials-and-bullish-technicals-3841930", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EmcurePharmaceu_mojoScore_3841930.png", "date": "2026-02-16 08:44:06", "description": "Emcure Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across key parameters including quality, valuation, financial trends, and technical indicators. This upgrade, effective from 13 February 2026, is underpinned by robust quarterly financial results, enhanced technical momentum, and a favourable market performance that outpaces broader benchmarks." }, { "title": "Emcure Pharmaceuticals Ltd Technical Momentum Shifts to Bullish Amid Strong Price Gains", "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-technical-momentum-shifts-to-bullish-amid-strong-price-gains-3841764", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EmcurePharmaceu_technicaldot_3841764.png", "date": "2026-02-16 08:05:35", "description": "Emcure Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, with technical indicators signalling a transition from a mildly bullish to a bullish trend. This upgrade is underpinned by positive movements in the MACD, moving averages, and other key technical parameters, suggesting growing investor confidence in the stock amid a volatile market backdrop." }, { "title": "Emcure Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-3827178", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/EmcurePharmaceu_mojoScore_3827178.png", "date": "2026-02-08 10:10:29", "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 February 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Are Emcure Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharmaceuticals-ltd-latest-results-good-or-bad-3822975", "imagepath": "", "date": "2026-02-05 19:34:47", "description": "Emcure Pharmaceuticals Ltd's latest financial results for Q3 FY26 reflect a continuation of its growth trajectory, with net sales reaching an all-time quarterly high of ₹2,363.48 crores, marking a year-on-year expansion of 20.42%. This growth demonstrates robust demand across key therapeutic segments and geographical markets. On a sequential basis, revenue advanced by 4.13% from the previous quarter, indicating sustained commercial momentum.\n\nHowever, the profitability metrics present a more complex picture. The consolidated net profit for the quarter was ₹230.54 crores, representing a significant year-on-year increase of 49.97%. Despite this, there was a sequential decline of 5.31% from the previous quarter's profit of ₹243.46 crores, which raises questions about the sustainability of profit margins. The operating profit margin slightly contracted to 20.85% from 20.95% in the prior quarter, although it rem..." } ], "total": 366, "sid": "10039308", "stock_news_url": "https://www.marketsmojo.com/news/emcure-pharmaceuticals-10039308" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS", "datetime": "03-Mar-2026", "details": "Allotment of Equity Shares pursuant to exercise of ESOPs under the Emcure-Employee Stock Option Scheme 2013.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "02-Mar-2026", "details": "Press Release titled Emcure Pharmaceuticals and Roche sign Distribution Agreement to strengthen Nephrology and Transplant Care in India", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation", "datetime": "20-Feb-2026", "details": "Investor Presentation for Investor Conferences to be attended by Officials of the Company on February 23 2026 and February 24 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25", "dt": "2025-08-14", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

16 Feb: Emcure upgraded to Buy on strong financials and bullish technicals

17 Feb: Technical momentum shifts amid mixed market signals

18 Feb: Downgrade to Hold reflecting mixed technical and valuation signals

20 Feb: Week closes at ₹1,438.55 (-3.37%) versus Sensex +0.39%

Week Open

₹1,488.65

Week CloseRead full news article

Emcure Pharmaceuticals Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-02-19 08:24:02

Emcure Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold as of 18 Feb 2026, reflecting a nuanced reassessment across quality, valuation, financial trends, and technical indicators. Despite strong financial performance and market-beating returns over the past year, evolving technical signals and valuation concerns have tempered the outlook, prompting a more cautious stance from analysts.

Read full news article

Emcure Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-17 08:07:32

Emcure Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of mid-February 2026. Despite a recent dip in price, key indicators such as the MACD and moving averages continue to suggest underlying strength, while other metrics like RSI and Dow Theory remain inconclusive. This article analyses the latest technical signals and market context to provide a comprehensive view of Emcure’s current positioning within the Pharmaceuticals & Biotechnology sector.

Read full news article

Emcure Pharmaceuticals Upgraded to Buy on Strong Financials and Bullish Technicals

2026-02-16 08:44:06

Emcure Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across key parameters including quality, valuation, financial trends, and technical indicators. This upgrade, effective from 13 February 2026, is underpinned by robust quarterly financial results, enhanced technical momentum, and a favourable market performance that outpaces broader benchmarks.

Read full news article

Emcure Pharmaceuticals Ltd Technical Momentum Shifts to Bullish Amid Strong Price Gains

2026-02-16 08:05:35

Emcure Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, with technical indicators signalling a transition from a mildly bullish to a bullish trend. This upgrade is underpinned by positive movements in the MACD, moving averages, and other key technical parameters, suggesting growing investor confidence in the stock amid a volatile market backdrop.

Read full news article

Emcure Pharmaceuticals Ltd is Rated Hold

2026-02-08 10:10:29

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Emcure Pharmaceuticals Ltd latest results good or bad?

2026-02-05 19:34:47

Emcure Pharmaceuticals Ltd's latest financial results for Q3 FY26 reflect a continuation of its growth trajectory, with net sales reaching an all-time quarterly high of ₹2,363.48 crores, marking a year-on-year expansion of 20.42%. This growth demonstrates robust demand across key therapeutic segments and geographical markets. On a sequential basis, revenue advanced by 4.13% from the previous quarter, indicating sustained commercial momentum. However, the profitability metrics present a more complex picture. The consolidated net profit for the quarter was ₹230.54 crores, representing a significant year-on-year increase of 49.97%. Despite this, there was a sequential decline of 5.31% from the previous quarter's profit of ₹243.46 crores, which raises questions about the sustainability of profit margins. The operating profit margin slightly contracted to 20.85% from 20.95% in the prior quarter, although it rem...

Read full news article